We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+23.23%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$690M
(-86%)
Cap. Flow
-$711M
Cap. Flow
% of AUM
-651.32%
Top 10 Holdings %
Top 10 Hldgs %
91.26%
Holding
65
New
6
Increased
2
Reduced
11
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$7.45M |
| 2 |
Acrivon Therapeutics
ACRV
|
+$3.61M |
| 3 |
CONMED
CNMD
|
+$2.28M |
| 4 |
Intuitive Surgical
ISRG
|
+$1.4M |
| 5 |
Hyperfine
HYPR
|
+$1.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$41.6M |
| 2 |
Agilent Technologies
A
|
+$41.1M |
| 3 |
Boston Scientific
BSX
|
+$37.1M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$36.7M |
| 5 |
Eli Lilly
LLY
|
+$33.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Miscellaneous | 0.02% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$12.5B
| $38.1M | 34.88% |
367,765
-391,273
| -52% | -$36.7M |
|
|
2
DexCom
DXCM
$34.3B
| $36.4M | 33.35% |
321,380
+67,880
| +27% | +$7.45M |
|
3
Cytokinetics
CYTK
$10B
| $7.53M | 6.91% |
164,440
-270,120
| -62% | -$11.6M |
|
|
4
Acrivon Therapeutics
ACRV
$88.3M
| $3.27M | 3% |
+284,201
| New | +$3.61M |
|
|
5
Hyperfine
HYPR
$88.4M
| $3.26M | 2.99% |
3,880,900
+1,131,500
| +41% | +$1.03M |
|
6
Alkermes
ALKS
$7.95B
| $2.87M | 2.63% |
110,000
-193,500
| -64% | -$4.63M |
|
|
7
CONMED
CNMD
$1.5B
| $2.44M | 2.23% |
+27,500
| New | +$2.28M |
|
8
Neurocrine Biosciences
NBIX
$15.7B
| $2.39M | 2.19% |
20,000
-1,720
| -8% | -$201K |
|
9
Syndax Pharmaceuticals
SNDX
$1.74B
| $1.78M | 1.63% |
70,000
-789,240
| -92% | -$18.4M |
|
|
KDNY
10
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.57M | 1.44% |
60,000
-206,830
| -78% | -$4.58M |
|
|
11
Intuitive Surgical
ISRG
$132B
| $1.53M | 1.4% |
+5,750
| New | +$1.4M |
|
|
BPMC
12
DELISTED
Blueprint Medicines
BPMC
| $1.31M | 1.2% |
30,000
-74,600
| -71% | -$3.58M |
|
13
Geron
GERN
$970M
| $1.21M | 1.11% |
500,000
-1,404,234
| -74% | -$3.15M |
|
14
Penumbra
PEN
$12.7B
| $1.11M | 1.02% |
+5,000
| New | +$978K |
|
15
Rocket Pharmaceuticals
RCKT
$424M
| $979K | 0.9% |
50,000
-395,140
| -89% | -$7.28M |
|
|
RAIN
16
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $960K | 0.88% |
+120,000
| New | +$753K |
|
17
Inspire Medical Systems
INSP
$1.78B
| $882K | 0.81% |
3,500
-34,740
| -91% | -$7.41M |
|
|
SILK
18
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $793K | 0.73% |
+15,000
| New | +$731K |
|
|
IMGN
19
DELISTED
Immunogen Inc
IMGN
| $744K | 0.68% |
150,000
-1,150,000
| -88% | -$6.24M |
|
|
EQRXW
20
DELISTED
EQRx, Inc. Warrant
EQRXW
| $9.45K | 0.01% |
35,239
| – | – |
|
|
EUCRW
21
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
| $4.34K | ﹤0.01% |
78,059
| – | – |
|
|
MSACW
22
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
| $2.68K | ﹤0.01% |
29,776
| – | – |
|
|
23
Agilent Technologies
A
$43.4B
| – | – |
-338,030
| Closed | -$41.1M |
|
|
24
AbbVie
ABBV
$451B
| – | – |
-310,250
| Closed | -$41.6M |
|
25
Abbott
ABT
$195B
| – | – |
-98,970
| Closed | -$9.58M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2022 Portfolio in Review
As of Q4 2022, HealthCor Management held 65 positions worth $109M, down 86% from $800M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
HealthCor Management withdrew a net $711M in Q4 2022, closing 43 positions and reducing 11 holdings. Its most notable exit was AbbVie, an estimated $41.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, HealthCor Management opened a new position in Acrivon Therapeutics worth $3.27M.
- HealthCor Management's largest Q4 2022 buy was Acrivon Therapeutics: 284,201 shares worth $3.27M.
- HealthCor Management added most to DexCom in Q4 2022, an estimated $7.45M increase.
- HealthCor Management's biggest Q4 2022 reduction was BioMarin Pharmaceuticals, cutting an estimated $36.7M.
- HealthCor Management fully exited AbbVie in Q4 2022, selling an estimated $41.6M.
- HealthCor Management's ten largest holdings make up 91% of its $109M portfolio in Q4 2022.
- HealthCor Management opened 6 new positions and closed 43 in Q4 2022.
- HealthCor Management's portfolio value fell 86% quarter-over-quarter to $109M.
Based on HealthCor Management's 13F filing for Q4 2022, filed 15 Feb 2023.